Connect with us

Technology

Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure to boost the market growth, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global clinical trial management system (CTMS) market size is estimated to grow by USD 1.86 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 14.27% during the forecast period. Increasing healthcare expenditure is driving market growth, with a trend towards increasing outsourcing of clinical trial process. However, rising cost of clinical trials poses a challenge. Key market players include Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

Deployment (On-premise and Cloud), End-user (Pharmaceutical and biotechnology companies, CROs, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd.

 

Key Market Trends Fueling Growth

In the pharmaceutical industry, the shift towards outsourcing drug discovery processes to subcontract laboratories has been a significant trend since 2011. This transformation has enabled small companies to focus on manufacturing and marketing activities while outsourcing research and testing to external resources. The increasing popularity of this approach is due to the substantial cost savings it offers, as companies can outsource these functions for a fraction of the cost of building and maintaining their own research facilities. This outsourcing trend is particularly prevalent in countries like the US, the UK, Germany, and Japan, which have been outsourcing drug discovery to emerging economies such as India and Brazil. The high volume of data generated during the drug discovery process necessitates the use of Clinical Trial Management Systems (CTMS) to manage and analyze this data effectively. The growing number of tests carried out in subcontract laboratories has led to a corresponding increase in demand for CTMS solutions. CTMS plays a crucial role in streamlining the clinical trial process, ensuring compliance with regulatory requirements, and facilitating data management and analysis. As the outsourcing trend continues, the demand for CTMS is expected to grow, providing opportunities for market expansion. 

The Clinical Trial Management System (CTMS) market is experiencing significant trends that are transforming the clinical trial landscape. Robust reporting and centralizing recruitment are key priorities for multinational companies and local CROs. ERegulatory, eSOURCE, accounting, and aggregate reporting provide network-wide visibility and oversight. Digitalization, personalized medicine, outsourcing, and externalization are driving growth in the market. Robust reporting, decentralized trial models, and evidence-based facilities are essential for regulatory compliance. ERegulatory, ERT, and Bioclinica are leading providers in Healthcare IT. Cloud-based CTMS, telemedicine solutions, and decentralized clinical trials are crucial in the current COVID-19 era. Costs, system security, backups, upgrades, and uptime consistency are critical considerations for CTM systems. AI and machine learning are enhancing trial efficiency and reducing costs. Vaccines and CTM systems are essential in the fight against COVID-19. The market is expected to continue growing, with investment in digitalization and regulatory policies being key drivers. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

Clinical trials are a crucial part of bringing new drugs to market, but their rising costs are a significant concern for the pharmaceutical industry. One major challenge is patient enrollment and retention, which can prolong the trial duration and increase expenses. According to various studies, the average cost per patient in the US for clinical trials is approximately USD41,117, with phase 3 trials being the most expensive, costing around USD20 million. Another factor contributing to the rising costs is the need for extensive clinical data collection due to new regulations. This can make trials complex and expensive, especially for drugs targeting chronic diseases. The longer a trial lasts, the more it costs, making clinical trial management systems essential to streamline the process. However, some clinical research associates may prefer manual work to cut costs, hindering the growth of the market. To address this issue, increasing patient awareness is the most feasible solution. By educating patients about the importance and benefits of clinical trials, the number of willing participants is likely to rise, reducing the overall cost and duration of trials. Pharmaceutical companies should focus on patient education rather than persuasion to ensure a successful clinical trial process.In the dynamic healthcare IT landscape, Clinical Trial Management Systems (CTMS) have become essential tools for managing complex clinical trials. However, implementing CTMS comes with challenges. Decentralized trials and the rise of vaccines require cloud-based CTMS for flexibility. Telemedicine solutions and COVID-NMA necessitate robust system security, backups, and upgrades. Centralization of data, growth, and AI/machine learning algorithms demand uptime consistency and automation. Clinical trial managers need access to data on devices like mobile workstations, laptops, and tablets via online dashboards. Trial planning, monitoring activities, regulatory procedures, supplies, finance, and subscription-based software upgrades require scalability. Add-ons, regulatory norms, document management processes, data quality, participant safety, and adherence to regulatory procedures are key considerations. Solutions like Clinion offer IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalability to address these challenges.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This clinical trial management system (ctms) market report extensively covers market segmentation by

Deployment 1.1 On-premise1.2 CloudEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 CROs2.3 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 On-premise- The Clinical Trial Management System (CTMS) market primarily consists of on-premises and cloud-based deployment models. On-premises CTMS offers enhanced data security and control, making it a preferred choice for large firms. However, the significant investment required for infrastructure and maintenance poses a challenge for smaller organizations. Conversely, cloud-based CTMS offers cost-effectiveness and ease of use. Major on-premises CTMS vendors include Siebel and IMPACT. Despite the high cost, large firms continue to prefer on-premises CTMS due to the perceived level of data security. This segment’s growth in the global CTMS market is anticipated to be driven by these factors during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022) – Download a Sample Report

Research Analysis

The Clinical Trial Management System (CTMS) market is a significant segment of Healthcare IT, facilitating the planning, execution, and management of clinical trials. With the increasing focus on decentralized clinical trials and the development of vaccines, CTMS solutions have gained prominence. Cloud-based CTMS is a popular choice due to its accessibility, scalability, and cost-effectiveness. Telemedicine solutions and IWRS/RTSM integrate seamlessly with CTMS, enhancing trial efficiency. EDC, eCOA, accruals, deviations, and robust reporting are essential features. Outsourcing and externalization to multinational companies and local CROs are common practices. Regulatory policies necessitate investment in CTMS solutions for ensuring compliance. Clario and other advanced systems offer features like ERT, making trial management more streamlined.

Market Research Overview

The Clinical Trial Management System (CTMS) market in Healthcare IT is experiencing significant growth due to the increasing adoption of decentralized clinical trials, particularly in the development of vaccines. Cloud-based CTMS solutions are gaining popularity for their accessibility and cost-effectiveness. Telemedicine solutions and AI-driven technologies, including machine learning algorithms and automation, are being integrated into CTMS to improve efficiency and data quality. Costs, system security, backups, and upgrades are key considerations for CTMS implementation. Uptime consistency, centralization of data, and regulatory norms are crucial for ensuring trial integrity and participant safety. Clinical trial managers require access to real-time data from devices such as mobile workstations, laptops, tablets, and online dashboards for effective trial planning, monitoring activities, and regulatory procedures. CTMS systems include modules for supplies, finance, and accounting on a subscription basis, with software upgrades and add-ons available for customization. Digitalization of clinical trials through eRegulatory, eSOURCE, IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalable, robust reporting is driving growth in the market. Centralizing recruitment and network-wide visibility are also important for oversight and personalized medicine initiatives. Outsourcing and externalization to local CROs and multinational companies are common practices in the industry. Clario and other trial models are embracing decentralized approaches and evidence-based facilities to streamline regulatory policies and investment in the sector.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

DeploymentOn-premiseCloudEnd-userPharmaceutical And Biotechnology CompaniesCROsOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-management-system-ctms-market-size-is-set-to-grow-by-usd-1-86-billion-from-2024-2028–increasing-healthcare-expenditure-to-boost-the-market-growth-technavio-302208770.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Former MLB Players Lead Ember Sports Mobile App, Bringing Pro-Level Training to Athletes Everywhere

Published

on

By

The MLB veterans say platform is a “game changer” for athletes at every level

HUNTSVILLE, Ala., April 21, 2026 /PRNewswire/ — Sports technology company Ember Sports is bringing professional-level baseball and softball training tools to athletes nationwide through a new mobile app developed in collaboration with former Major League Baseball players and coaches Brady Clark and Damon Mashore. Designed to make advanced player development more accessible, the platform delivers real-time performance insights using a mobile device, eliminating the need for costly hardware or exclusive facility-based systems.

Clark and Mashore, former MLB outfielders with a combined 18 seasons in the major leagues, now serve in leadership roles at Ember, helping guide the platform’s development and real-world application. Clark is the company’s Chief Operating Officer, while Mashore serves as Chief Integration Officer. Their involvement reflects a broader shift toward making the types of training tools once reserved for professional athletes available to players at every level.

Leveraging built-in iOS video capture, Ember’s mobile app provides immediate, actionable feedback through tools such as its Hitting and Pitching Analyzers. Athletes can review performance using video replay, telestration and side-by-side comparisons, allowing for deeper analysis of swing mechanics, pitch execution and overall performance.

The platform also introduces virtual reality capabilities designed to enhance training in ways that are difficult to replicate in traditional environments. A key feature is Ember’s ability to teach pitch tunneling, an advanced skill in which multiple pitches follow the same initial path before breaking differently, making them more difficult for batters to recognize and hit.

“Teaching hitters how to see the ball the way MLB players do has always been one of the hardest things to train,” Mashore said. “With Ember’s technology, we’re able to simulate that in a meaningful way. That’s a big step forward.”

With more than 25 million baseball and softball athletes across the United States, access to advanced training tools has often been limited by cost and availability. Ember aims to expand that access with a subscription starting at $12.99 per month, delivering data and insights traditionally available only at the professional level.

“This is truly disruptive technology because of how easy it is to use and the low-cost barrier,” said Clark. “It opens the door for more players at every level. From the conversations Damon and I have had across our baseball network, the reaction is usually, ‘I can’t believe you guys can do this.’ Especially with VR, no one has been able to teach how we ‘see’ the ball.”

By removing the need for specialized equipment and training facilities, Ember is expanding access to high-level development tools once reserved for the big leagues. Its virtual reality platform places athletes in customizable environments that simulate live pitching with adjustable speed, movement and location, helping improve pitch recognition, timing and decision-making.

“You’re either on the forefront of technology or you’re behind the game,” Mashore added. “Being able to deliver this level of insight to players outside of the professional level at such an affordable cost is simply a game changer.”

With leadership rooted in decades of professional playing and coaching experience, Ember Sports is entering the market with strong credibility and a focus on accessibility, aiming to bring professional-grade training within reach for the next generation of baseball and softball athletes.

To learn more about Ember Sports, visit EmberSports.com

About Ember Sports
Ember Sports is a sports technology company redefining baseball and softball training through accessible and affordable data-driven performance tools. Available on iOS and VR platforms, Ember’s Hitting Analyzer, Pitching Analyzer and immersive VR experiences deliver real-time metrics, video capture and advanced pitch recognition training, all without the need for expensive hardware. By removing traditional costs and facility barriers, Ember is driving the future of training for the next generation of athletes. 

Contact: 
Katie Schmidt 
Public Relations Manager 
InnoVision Marketing Group 
PR@InnoVisionMarketingGroup.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/former-mlb-players-lead-ember-sports-mobile-app-bringing-pro-level-training-to-athletes-everywhere-302748130.html

SOURCE Ember Sports

Continue Reading

Technology

AtkinsRéalis to acquire Australia-based Engineering Consultancy WGA

Published

on

By

MONTREAL, April 21, 2026  /CNW/ – AtkinsRéalis Group Inc. (TSX: ATRL), a world-class engineering services and nuclear company with offices around the world, announced today that it has entered into a scheme implementation deed to acquire Wallbridge Gilbert Aztec (WGA), a leading Australian and New Zealand engineering and project management consultancy firm.

The proposed acquisition represents a significant step in AtkinsRéalis’ ambition to build a national platform with strong local presence in key states and markets across Australia and to capitalize on Australia’s significant investment programs in infrastructure and other high growth client end-markets, such as Defence and Power & Renewables. The addition of WGA’s 800 professionals strengthens AtkinsRéalis’ delivery capacity and sector depth in priority infrastructure markets, including transportation, water, power and renewables, ports and marine, defence-related infrastructure, resources and industrial. Founded in 1976, WGA delivers long-term infrastructure programmes, supported by deep regional capability and strong client relationships across both countries.

“This transaction reflects our continued investment in the AMEA region, in line with our ‘Delivering Excellence, Driving Growth’ strategy,” said Ian L. Edwards, President and Chief Executive Officer of AtkinsRéalis. “Australia is a priority market for us, where we are rapidly building scale and capability. WGA has deep regional expertise, strong client relationships and highly regarded capability across sectors that are closely aligned with our own. By bringing our teams together, we would be well positioned to deliver integrated solutions and better outcomes for our clients, while creating new opportunities for our people.”

The acquisition would reinforce AtkinsRéalis’ strategy of combining global capability with local proximity. WGA would gain access to AtkinsRéalis’ global systems, digital capabilities and technical excellence. This approach would support continuity for clients and employees, while creating expanded opportunities for collaboration, career development and technical growth.

“Joining AtkinsRéalis would mark a significant next step for WGA,” said Ben Stapleton, Joint Managing Director of WGA. “For more than 40 years, we’ve delivered practical, high-quality engineering solutions by being regionally embedded, backing our people, and building trusted, long-term partnerships with our clients. Becoming part of AtkinsRéalis would enable us to build on these strengths by connecting our team to broader technical expertise, global opportunities and investment, supporting and accelerating the next phase of our growth across Australia and New Zealand. Importantly, we can do this while staying true to what makes WGA unique, with strong alignment across our cultures and strategic priorities.”

The proposed transaction will be implemented by way of a scheme of arrangement under Part 5.1 of the Australian Corporations Act and is subject to customary closing conditions, including WGA shareholders’ approval, and the receipt of necessary regulatory and court approvals.

About AtkinsRéalis

Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-leading engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world’s infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at www.atkinsrealis.com or follow us on LinkedIn.

About WGA

Wallbridge Gilbert Aztec (WGA) is a multi‑disciplinary engineering and project management consultancy with more than 40 years of experience delivering complex infrastructure across Australia and New Zealand. Employee‑owned and regionally embedded, WGA employs over 800 people operating from offices across South Australia, Western Australia, Victoria, Queensland, New South Wales, the Northern Territory and New Zealand.

WGA supports clients across the full project lifecycle through engineering, project management and advisory services, with established capability in transport, water, power and renewables, ports and marine, defence‑related infrastructure, buildings, resources and industrial, urban development and sport and recreation sectors. Known for strong local leadership, long‑term client relationships and practical, buildable solutions, WGA operates with a delivery model aligned to how and where infrastructure is delivered. Learn more at wga.com.au.

Forward-Looking Statements

References in this press release to the “Company”, “AtkinsRéalis”, “we”, us” and “our” mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company’s expectations or strategies, including with respect to the acquisition of WGA (the “Transaction”), constitute “forward-looking statements” and can be identified by the use of the conditional or forward-looking terminology such as “estimates”, “expects”, “forecasts”, “intends”, “may”, “objective”, “plans”, “projects”, “should”, “will”, “likely”, or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company’s current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company’s business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof and are subject to important risks and uncertainties, including the satisfaction of all closing conditions (which includes obtaining WGA shareholders’ approval), the receipt of necessary regulatory and court approvals, and the successful completion of the Transaction; management’s estimates and expectations in relation to future economic and business conditions and other factors in relation to the Transaction and resulting impact on growth and accretion in various financial metrics; and the absence of significant undisclosed costs or liabilities associated with the Transaction.

The forward-looking statements herein reflect the Company’s expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement.

SOURCE AtkinsRéalis

Continue Reading

Technology

Rockwell Automation to Demonstrate Cloud‑Connected Factory Design and Industrial Operations with AWS at Hannover Messe 2026

Published

on

By

DUSSELDORF, Germany, April 21, 2026 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, will demonstrate new approaches to factory design and industrial operations at Hannover Messe 2026, highlighting how cloud‑connected data, digital twins, autonomous systems and industrial AI can work together to support more flexible, resilient manufacturing. The joint demonstrations will run 20-24 April at the Amazon Web Services (AWS) booth in Hall 15, Stand D76.

The presentations combine Rockwell’s industrial automation, factory design software and autonomous mobile robots (AMRs) with AWS cloud and analytics capabilities, illustrating how manufacturers can connect physical operations with cloud‑based intelligence to gain deeper visibility and drive continuous optimization. 

As part of the demonstration, Amazon’s Global Engineering Services team will show how it uses Rockwell’s Emulate3D™ dynamic digital twin software to create digital twins of fulfillment and industrial environments. Digital twin models enable teams to evaluate layouts and operational sequences early in the design phase, including physics-based simulation that connects to programmable logic controllers (PLCs), to complete testing and commissioning activities more efficiently. The digital twin is used pre-launch to test designs without physical hardware and discover errors before commissioning and then again post-launch to validate performance.

“Manufacturers are being asked to operate with greater agility while managing increased complexity across production and logistics,” said Felix Tang, senior manager strategic partnerships, Rockwell Automation. “By combining our industrial automation and domain expertise with AWS, we’re showing how manufacturers can connect data from machines, robots and material flow into a shared foundation that supports smarter decision‑making at scale.”

In collaboration with Amazon and AWS, Rockwell will show how digital twin environments can be deployed using a cloud-based architecture on AWS. The approach reflects how manufacturers can use cloud infrastructure to support distributed factory design and commissioning activities.

The companies will also show autonomous operations enabled by mobile robots. Industrial operations have traditionally relied on fragmented data from production equipment, material handling systems and enterprise applications. This lack of integration makes it difficult to understand how decisions in one area, such as logistics or workforce deployment, impact overall performance.

At Hannover Messe, Rockwell and AWS will show how these challenges can be addressed through a connected, cloud‑based scenario, using a simplified production logistics workflow to represent real‑world operations. While AMRs from OTTO, a Rockwell Automation company, manage material movement, a humanoid robot will demonstrate human‑centric tasks such as handling materials and engaging with visitors. Together, these systems generate operational data that can be aggregated through Rockwell software and securely connected to AWS, enabling insights beyond the factory floor across production, logistics and workforce activities.

The display highlights a shared data foundation, where data from autonomous systems is captured once and reused across monitoring, analytics and optimization workflows. By combining autonomous robotics, industrial software and cloud‑based analytics and AI, the demonstration shows how manufacturers can remove silos and shift from reactive to more adaptive, data‑driven operations.

In addition to existing offerings, Rockwell plans to make selected industrial software applications available through AWS Marketplace, including:

Emulate3D – Software used to develop digital twins for virtual factory design and commissioning activitiesOTTO Fleet Manager – Software used to manage and monitor autonomous mobile robot fleetsFactoryTalk Optix – A visualization and integration platform supporting HMI, IIoT and edge‑based applications

Attendees interested in seeing these innovative solutions from Rockwell and AWS can register for a free ticket to Hannover Messe.

About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries as of fiscal year end 2025. To learn more about how we are bringing Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.

Logo – https://mma.prnewswire.com/media/1981317/Rockwell_Automation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/rockwell-automation-to-demonstrate-cloudconnected-factory-design-and-industrial-operations-with-aws-at-hannover-messe-2026-302747440.html

Continue Reading

Trending